RxDoctor Payments Data

Aaron Rosenberg

General Practice · Mequon, WINPI 1306237417

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,475 of the $20,813 with a category attached, or 64.7%. AbbVie accounts for 82.9% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $5,643 and has fallen 90.1% since, to $559 in 2025. Among general practice clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,813in general payments, 2019–2025

Across 264 payments — averaging $78.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Gilead$899
  • Lilly USA, LLC$570
  • Orexo US, Inc.$440
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$259
  • Indivior Inc.$202
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$13,47565%
  • Travel & lodging$2,42912%
  • Food & beverage$4,85323%
  • Education$550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,813 in reported general payments places this provider in the 95th percentile of 1,554 general practice providers in Wisconsin.

See all general practice providers in Wisconsin

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$13,477
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$9,731
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl51$9,282
Adzenys Xr-OdtAmphetamine11$5,388
Divalproex Sodium14$1,338
Haloperidol14$1,086
Gabapentin27$623
Tizanidine Hcl28$383
Fluoxetine Hcl22$358
Methylphenidate ErMethylphenidate Hcl11$299
Metformin Hcl17$288
Levetiracetam14$271
Omeprazole15$267
Methylphenidate Hcl11$261
Amlodipine Besylate50$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$13,47723 claims
Indivior Inc.Suboxone$202$9,73114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,554 general practice providers in Wisconsin.

Other general practice in Mequon

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →